Last update 21 Nov 2024

Influenza vaccine quadrivalent(Research Fdn for Microbial Diseases of Osaka University)

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Inactivated vaccine, Prophylactic vaccine, Multivalent vaccine

Synonyms

Influenza Ha Vaccine 'Biken', Influenza vaccine quadrivalent, Seasonal influenza HA vaccine

+ [5]

Target

hemagglutinin

Mechanism

hemagglutinin modulators(Influenza virus hemagglutinin glycoproteins modulators)

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza, Human

Inactive Indication-

Originator Organization

Research Fdn for Microbial Diseases of Osaka University

Active Organization

Biken Techno Corp.MSD KKMitsubishi Tanabe Pharma Factory Ltd.

+ [1]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (26 Mar 1982),

Influenza, Human

Regulation-

100 Clinical Results associated with Influenza vaccine quadrivalent(Research Fdn for Microbial Diseases of Osaka University)

100 Translational Medicine associated with Influenza vaccine quadrivalent(Research Fdn for Microbial Diseases of Osaka University)

100 Patents (Medical) associated with Influenza vaccine quadrivalent(Research Fdn for Microbial Diseases of Osaka University)

Literatures (Medical) associated with Influenza vaccine quadrivalent(Research Fdn for Microbial Diseases of Osaka University)

01 Sep 2022·American Journal of Kidney DiseasesQ1 · MEDICINE

Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients

Q1 · MEDICINE

Article

Author: Manley, Harold J ; Miskulin, Dana C ; Hsu, Caroline M ; Johnson, Doug S ; Lacson, Eduardo K ; Meyer, Klemens B ; Kapoian, Toros ; Chen Li, Nien ; Weiner, Daniel E ; Hayney, Mary S ; Aweh, Gideon

RATIONALE & OBJECTIVEHigh-dose influenza vaccine provides better protection against influenza infection in older adults than standard-dose vaccine. We compared vaccine seroresponse among hemodialysis patients over a period of 4 months after administration of high-dose trivalent inactivated (HD-IIV3), standard-dose quadrivalent inactivated (SD-IIV4), or quadrivalent recombinant quadrivalent (RIV4) influenza vaccine.STUDY DESIGNProspective observational study.SETTING & PARTICIPANTSPatients at 4 hemodialysis clinics who received influenza vaccine.EXPOSUREType of influenza vaccine.OUTCOMEHemagglutination inhibition (HI) titers were measured at baseline and at 1, 2, 3, and 4 months after vaccination. The primary outcome was seroprotection rates at HI titers of at least 1:40 and at least 1:160 (antibody levels providing protection from infection in approximately 50% and 95% of immunocompetent individuals, respectively) at 1, 2, 3, and 4 months after vaccination.ANALYTICAL APPROACHWe calculated geometric mean titer as well as seroprotection and seroconversion rates. Adjusted generalized linear models with additional trend analyses were performed to evaluate the association between vaccine type and outcomes.RESULTS254 hemodialysis patients were vaccinated against influenza with HD-IIV3 (n = 141), SD-IIV4 (n = 36), or RIV4 (n = 77). A robust initial seroresponse to influenza A strains was observed after all 3 vaccines. Geometric mean titer and seroprotection (HI titer ≥1:160) rates against influenza A strains were higher and more sustained with HD-IIV3 than SD-IIV4 or RIV4. More than 80% of patients vaccinated with HD-IIV3 were seroprotected (HI titer ≥1:160) at month 4 (P < 0.001), whereas, among patients vaccinated with SD-IIV4 or RIV4, seroprotection rates were similar to those at baseline. Seroprotection rates were lower against B strains for all vaccines.LIMITATIONSBecause of the use of observational data, bias from unmeasured confounders may exist. Some age subgroups were small in number. Clinical outcome data were not available.CONCLUSIONSHemodialysis patients exhibited high seroprotection rates after all 3 influenza vaccines. The seroresponse waned more slowly with HD-IIV3 compared with SD-IIV4 and RIV4 vaccines.

01 May 2020·Colloids and Surfaces B: BiointerfacesQ2 · ENGINEERING & TECHNOLOGY

Zn-HA/Bi-HA biphasic coatings on Titanium: Fabrication, characterization, antibacterial and biological activity

Q2 · ENGINEERING & TECHNOLOGY

Article

Author: Song, Xian ; Lei, Ting ; Zheng, Yaping ; Bi, Qing ; Yin, Ping ; Chen, Yujia

Hydroxyapatite (HA) coatings have been of important as biocompatible coatings for dental and bone tissue engineering application. However, the poor antibacterial performance and weak biological activity of HA coatings limited their clinical applications. As a strategy to improve the antibacterial performance and biological activity of HA, Zinc and bismuth ions were incorporated into HA lattice by substituting Ca²⁺ ions, respectively, and thus zinc substituted hydroxyapatite/bismuth substituted hydroxyapatite (Zn-HA/Bi-HA) biphasic coatings on titanium plates with various ratios were fabricated via sol-gel and dip-coating processes. The purity of the Zn-HA and Bi-HA phase was confirmed by X-ray diffraction (XRD) test. The biphasic coatings showed slower dissolution rate than pure HA coating. Furthermore, the Zn-HA/Bi-HA coatings reveal good biomineralization activity in simulated body fluid (SBF) by forming regular spherical apatite agglomerates. Moreover, the biphasic Zn-HA/Bi-HA coatings exhibited that improved antimicrobial activity against Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) as compared to pure HA coatings. The CCK-8 assays demonstrate Zn-HA/Bi-HA coatings showed no toxicity to MG63 cells, and the Zn-HA/Bi-HA2 (Zn-HA:Bi-HA=64:1) coating is more effective to enhance the proliferation of MG63 cells compared to other coatings. This finding suggests Zn-HA/Bi-HA biphasic coatings are promising candidates for biomedical applications.

01 Oct 2014·Journal of Dermatological TreatmentQ4 · MEDICINE

Efficacy and safety of a new monophasic hyaluronic acid filler in the correction of nasolabial folds: a randomized, evaluator-blinded, split-face study

Q4 · MEDICINE

Article

Author: Kim, Beom Joon ; Kim, Myoung Shin ; Won, Chong Hyun ; Choi, Jee Ho ; Rhee, Do Young ; Lee, Mi Woo ; Lim, Sung Hoon ; Chang, Sung Eun ; Park, Gyeong Hun ; Noh, Tai Kyung ; Moon, Kee Chan ; An, Jee Soo

BACKGROUNDHyaluronic acid (HA) fillers are frequently used for the correction of facial soft-tissue defects.OBJECTIVETo compare the efficacy and safety of a novel monophasic HA filler (mono-HA), and a well-studied biphasic HA filler (bi-HA), in the treatment of moderate to severe nasolabial folds.METHODSIn this randomized, evaluator-blinded, split-face comparative study, subjects were randomized for injections with mono-HA or bi-HA on the left or right side of the face. Efficacy was determined by calculating the change in the Wrinkle Severity Rating Score (WSRS) relative to baseline. Local safety was assessed on the basis of subject diary entries which recorded erythema, swelling, induration, pruritus, irritation, mass, hematoma, pain, and dryness.RESULTSAt week 24, the mean improvement in the WSRS from baseline was 2.18 ± 0.42 for the mono-HA side and 2.16 ± 0.41 for the bi-HA side. Both fillers were well-tolerated and adverse reactions were mild and transient in most cases.CONCLUSIONSMono-HA has a non-inferior efficacy to bi-HA in the treatment of moderate to severe nasolabial folds.

100 Deals associated with Influenza vaccine quadrivalent(Research Fdn for Microbial Diseases of Osaka University)

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Influenza, Human	JP	Mitsubishi Tanabe Pharma Factory Ltd.	26 Mar 1982
Influenza, Human	JP	MSD KK	26 Mar 1982
Influenza, Human	JP	Biken Techno Corp.	26 Mar 1982

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Influenza vaccine quadrivalent(Research Fdn for Microbial Diseases of Osaka University)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation